Veracyte, Inc. (VCYT)
NASDAQ · Healthcare
$57.26-3.16%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $4.55B
- P/E ratio
- —
- EPS
- —
- Volume
- 1,606,031
- 52-week high
- —
- 52-week low
- —
- Open
- $58.86
- Day high
- $59.83
- Day low
- $56.57
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $517.15M | $66.35M | $0.82 |
| 2024 | $445.76M | $24.14M | $0.31 |
| 2023 | $361.05M | -$74.4M | -$1.02 |
| 2022 | $296.54M | -$36.56M | -$0.51 |
| 2021 | $219.51M | -$75.56M | -$1.11 |
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
- CEO
- Marc Stapley
- Employees
- 755
- Country
- US
- IPO date
- Oct 29, 2013
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Veracyte, Inc.'s stock price today?
- VCYT is trading at $57.26 as of Jul 20, 2026.
- What is Veracyte, Inc.'s market cap?
- Veracyte, Inc. (VCYT) has a market capitalization of $4.55B.
- Does Veracyte, Inc. pay a dividend?
- Veracyte, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Veracyte, Inc. in?
- Veracyte, Inc. operates in the Healthcare sector.